Experimental therapy

Swiss physicians contacted an international pharmaceutical company regarding the availability of a medicinal product not authorised in Switzerland for the treatment of a fatal disease. The product was intended for the treatment of a small number of patients for whom the available standard therapy was unsuitable or for whom all therapeutic options had been exhausted. We advised the company in order to enable the availability of the medicinal product in these cases.